{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:43:43Z","timestamp":1787507023593,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.semradonc.2022.01.005","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T06:47:35Z","timestamp":1654584455000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["DCIS: Risk Assessment in the Molecular Era"],"prefix":"10.1016","volume":"32","author":[{"given":"Christin A.","family":"Knowlton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena S.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2022.01.005_bib0001","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","article-title":"Detection of ductal carcinoma in situ in women undergoing screening mammography","volume":"94","author":"Ernster","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0002","first-page":"7","article-title":"A: Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0003","series-title":"Cancer Facts & Figures","year":"2021"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0004","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djp482","article-title":"Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes","volume":"102","author":"Virnig","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.molonc.2013.07.005","article-title":"Progression from ductal carcinoma in situ to invasive breast cancer: Revisited","volume":"7","author":"Cowell","year":"2013","journal-title":"Mol Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0006","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/modpathol.2014.141","article-title":"Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up","volume":"28","author":"Sanders","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0007","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.1978.03280450035020","article-title":"Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone","volume":"239","author":"Betsill","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0008","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer NCCN Guidelines Version 5.2021. Available at https:\/\/nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed July 25, 2021"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0009","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1998.16.2.441","article-title":"Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(99)06341-2","article-title":"Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853","volume":"355","author":"Julien","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0011","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(03)13859-7","article-title":"Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial","volume":"362","author":"Houghton","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0012","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial","volume":"32","author":"W\u00e4rnberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0013","first-page":"162","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"41","author":"Correa","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0014","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0016","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-017-4410-6","article-title":"Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers","volume":"166","author":"Withrow","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0017","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V","article-title":"A prognostic index for ductal carcinoma in situ of the breast","volume":"77","author":"Silverstein","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0018","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","article-title":"Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ","volume":"28","author":"Rudloff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0019","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2015.65.1869","article-title":"Vaz-Luis I: Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma In situ: A population-based longitudinal cohort study","volume":"34","author":"Sagara","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2006.03.009","article-title":"Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast","volume":"65","author":"Smith","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0021","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1245\/s10434-017-6254-z","article-title":"Molecular genomic testing for breast cancer: Utility for surgeons","volume":"25","author":"Fayanju","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"74","key":"10.1016\/j.semradonc.2022.01.005_bib0022","article-title":"Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use","volume":"23","author":"Schaafsma","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0023","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"JNCI"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603","article-title":"The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA)","volume":"37","author":"Kanbayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0026","first-page":"96","article-title":"Ductal carcinoma in situ (DCIS)\u2014precision medicine for de-escalation","volume":"13","author":"Rakovitch","year":"2021","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-013-2813-6","article-title":"Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)","volume":"143","author":"Wong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0028","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1200\/JCO.2009.21.8560","article-title":"Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0029","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","article-title":"Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study","volume":"33","author":"Solin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","article-title":"RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation","volume":"33","author":"McCormick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0031","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ijrobp.2018.08.048","article-title":"Randomized trial evaluating radiation following surgical excision for \u201cgood risk\u201d DCIS: 12-year report from NRG\/RTOG 9804","volume":"102","author":"McCormick","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: Long-term report from NRG Oncology\/RTOG 9804","author":"McCormick","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0033","doi-asserted-by":"crossref","first-page":"djv263","DOI":"10.1093\/jnci\/djv263","article-title":"Trends in treatment patterns and outcomes for ductal carcinoma in situ","volume":"107","author":"Worni","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0034","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10549-017-4436-9","article-title":"Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: Findings from the National Cancer Database, 2004-2013","volume":"166","author":"Sagara","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-9610(03)00265-4","article-title":"The University of Southern California\/Van Nuys prognostic index for ductal carcinoma in situ of the breast","volume":"186","author":"Silverstein","year":"2003","journal-title":"Am J Surg"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0036","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jncimonographs\/lgq040","article-title":"Choosing treatment for patients with ductal carcinoma in situ: Fine tuning the University of Southern California\/Van Nuys Prognostic Index","author":"Silverstein","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0037","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1006437902770","article-title":"Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: Practical considerations","volume":"61","author":"de Mascarel","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0038","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1524-4741.2007.00443.x","article-title":"The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: A retrospective analysis","volume":"13","author":"Asjoe","year":"2007","journal-title":"Breast J"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0039","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.23089","article-title":"An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ","volume":"110","author":"MacAusland","year":"2007","journal-title":"Cancer"},{"issue":"405","key":"10.1016\/j.semradonc.2022.01.005_bib0040","article-title":"Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?","volume":"3","author":"Kim","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0041","unstructured":"MSKCC: Breast cancer nomogram: Ductal carcinoma in situ (DCIS) recurrence. http:\/\/nomograms.mskcc.org\/breast\/DuctalCarcinomaInSituRecurrencePage.aspx. Accessed on August 22, 2021"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.32.3717","article-title":"Nomogram for risk of relapse after breast-conserving surgery in ductal carcinoma in situ","volume":"29","author":"Mazouni","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0043","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1200\/JCO.2010.32.6850","article-title":"Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability","volume":"29","author":"Ballehaninna","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PPO.0000000000000025","article-title":"Local relapse after breast-conserving therapy for ductal carcinoma in situ: A European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram","volume":"20","author":"Sweldens","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0045","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clon.2014.08.004","article-title":"Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast","volume":"26","author":"Wang","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0046","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2011.36.4976","article-title":"Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision","volume":"30","author":"Yi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0047","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-013-2755-z","article-title":"Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43","volume":"142","author":"Siziopikou","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.semradonc.2022.01.005_bib0048","article-title":"Primary results of NRG Oncology\/NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy","volume":"38","author":"Cobleigh","year":"2020","journal-title":"J Clinical Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0049","doi-asserted-by":"crossref","first-page":"936","DOI":"10.18632\/oncotarget.27948","article-title":"Multigene tests for breast cancer: the physician's perspective","volume":"12","author":"Cognetti","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0051","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0052","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","article-title":"A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone","volume":"152","author":"Rakovitch","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0054","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-018-4693-2","article-title":"Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: A combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies","volume":"169","author":"Rakovitch","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clbc.2018.07.018","article-title":"Including the ductal carcinoma-in-situ (DCIS) score in the development of a multivariable prediction model for recurrence after excision of DCIS","volume":"19","author":"Paszat","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0056","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/djq101","article-title":"Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis","volume":"102","author":"Kerlikowske","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0057","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0058","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","article-title":"Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy","volume":"26","author":"Weinmann","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0059","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaa179","article-title":"Nofech-Mozes S: 21-Gene assay and breast cancer mortality in ductal carcinoma in situ","volume":"113","author":"Rakovitch","year":"2021","journal-title":"JNCI"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0060","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jso.23933","article-title":"The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score\u2122 result","volume":"111","author":"Alvarado","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0061","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1245\/s10434-016-5583-7","article-title":"Clinical utility of the 12-Gene DCIS Score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ","volume":"24","author":"Manders","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0062","unstructured":"The PREDICT Registry for DCIS Patients with DCISionRT Testing (PREDICT). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03448926. Accessed August 21, 2021"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0063","article-title":"The clinical utility of DCISionRT\u00ae on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery","author":"Shah","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0064","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-019-07537-y","article-title":"Comparison of local recurrence risk estimates after breast-conserving surgery for DCIS: DCIS Nomogram versus refined Oncotype DX Breast DCIS Score","volume":"26","author":"Van Zee","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0065","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1200\/JCO.2016.67.8532","article-title":"Cost effectiveness of the Oncotype DX DCIS Score for guiding treatment of patients with ductal carcinoma in situ","volume":"34","author":"Raldow","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0066","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa004","article-title":"Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ","volume":"4","author":"Raldow","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0067","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clbc.2020.10.007","article-title":"Cost-effectiveness analysis of biological signature DCISionRT use for DCIS treatment","volume":"21","author":"Kim","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0068","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.prro.2016.06.011","article-title":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ","volume":"6","author":"Morrow","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0069","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0070","unstructured":"Management of low-risk (grade I and II) DCIS (LORD). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02492607. Accessed on August 22, 2021"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0071","first-page":"325","article-title":"The LORIS trial: randomising patients with low or intermediate-grade ductal carcinoma in situ (DCIS) to surgery or active monitoring","volume":"167","author":"Wallis","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0072","unstructured":"LORIS The LOw RISk DCIS trial: A phase III trial of surgery versus active monitoring for low risk ductal carcinoma in situ (DCIS), protocol version 4.0. Available at https:\/\/www.birmingham.ac.uk\/Documents\/college-mds\/trials\/crctu\/Loris\/LORIS-Trial-Protocol-Vn4.0-15.03.16.pdf. Accessed on August 22, 2021"},{"key":"10.1016\/j.semradonc.2022.01.005_bib0073","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyx059","article-title":"Current approach and future perspective for ductal carcinoma in situ of the breast","volume":"47","author":"Kanbayashi","year":"2017","journal-title":"Jpn J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429622000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429622000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:51:55Z","timestamp":1760950315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429622000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1053429622000054"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2022.01.005","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DCIS: Risk Assessment in the Molecular Era","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2022.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}